Latest news with #BlueJetHealthcare
Economic Times
19-05-2025
- Business
- Economic Times
BSE and Adani Enterprises among stocks that HDFC Mutual Fund bought and sold in April
HDFC Mutual Fund, the third largest mutual fund in India based on assets managed, added more stocks of BSE and 469 other stocks to its portfolio in April whereas reduced its stake in Adani Enterprises and 119 other stocks in the same period, according to the monthly data shared by Prime Database. Among the stocks where the fund house increased its allocation includes BSE, Hyundai Motor India, Power Grid Corporation of India, Adani Ports & Special Economic Zone, HDFC Bank, HCL Technologies, Eicher Motors, Bharti Airtel, Hindalco Industries, Yes Bank, and Eternal. Also Read | Sensex @82,300: Should mutual fund investors alter their investment strategy? The stocks where it reduced its stake included IRCTC, HUDCO, Federal Bank, ITC Hotels, ACC, Bank of India, Gail (India), Nippon Life AMC, Indian Energy Exchange, Radico Khaitan, Trent, Siemens, HAL, Tata Consumer Products, REC, IndusInd Bank, and SBI, and fund house did not add any new stock to its portfolio in the said time period. HDFC Mutual Fund made a complete exit from Blue Jet Healthcare. Around 10,671 shares of Blue Jet Healthcare were sold out from the portfolio worth Rs 0.94 crore. There were around 19 unique stocks in the portfolio of the fund house which included Bajaj Healthcare, BEML Land Assets, Delta Corporation, Diffusion Engineers, Epack Durables, Goodyear India, OCCL, Ramco Systems, TV Today Network, and Epack industry-wise holding of the fund house was highest in financial services of around 33.78%, 15.84% in consumer discretionary. Around 3.59% was in telecommunication, and 5.69% in energy, and 5.59% in Read | Railways PSU ETF delivers 16% in a week. Is this the right opportunity for portfolio diversification?In FMCG, the allocation was 4.16%, followed by services which had an allocation of 3.05%. The fund house had an allocation of 9.19% in healthcare, 7.87% in IT, and 8.65% in lowest allocation was in utilities of around 2.59%.The fund house had a total AUM of Rs 8.24 lakh crore as on April 30, 2025 and manages 134 schemes.
Mint
16-05-2025
- Business
- Mint
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 16 May 2025
Breakout stocks buy or sell: A widespread buying surge swept through the Indian stock market on Thursday, May 15, pushing the key indices—the Sensex and the Nifty 50—up by more than 1 percent each. The Sensex surged 1,200 points, or 1.48 percent, to close at 82,530.74, while the Nifty 50 climbed 395 points, or 1.60 percent, finishing at 25,062.10. Meanwhile, the BSE Midcap index gained 0.67 percent, and the Smallcap index advanced 0.94 percent. Sumeet Bagadia, Executive Director at Choice Broking, believes that the Indian stock market sentiment has turned bullish as the Nifty 50 index has closed above 25,000 levels. Speaking on the outlook of Indian stock market, Bagadia said, ' The 50- stock index is now poised to touch 25,400 and 25,800 levels. In this bull trend, one should maintain stock-specific approach and look at those stocks that are looking strong on the technical chart. Looking at breakout stocks can be a good option." Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Blue Jet Healthcare, Steelcast, Cochin Shipyard, SML Isuzu, and Anupam Rasayan India. 1] Blue Jet Healthcare: Buy at ₹ 840, target ₹ 900, stop loss ₹ 810; 2] Steelcast: Buy at ₹ 990, target ₹ 1060, stop loss ₹ 955; 3] Cochin Shipyard: Buy at ₹ 1812, target ₹ 1930, stop loss ₹ 1750; 4] SML Isuzu: Buy at ₹ 1680, target ₹ 1800, stop loss ₹ 1630; 5] Anupam Rasayan India: Buy at ₹ 958, target ₹ 1020, stop loss ₹ 925. Disclaimer: The views and recommendations provided in this analysis are those of individual analysts or broking companies, not Mint. We strongly advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and individual circumstances may vary.
Business Standard
14-05-2025
- Business
- Business Standard
Blue Jet Healthcare standalone net profit rises 177.68% in the March 2025 quarter
Sales rise 85.08% to Rs 340.45 crore Net profit of Blue Jet Healthcare rose 177.68% to Rs 110.10 crore in the quarter ended March 2025 as against Rs 39.65 crore during the previous quarter ended March 2024. Sales rose 85.08% to Rs 340.45 crore in the quarter ended March 2025 as against Rs 183.95 crore during the previous quarter ended March 2024. For the full year,net profit rose 86.38% to Rs 305.20 crore in the year ended March 2025 as against Rs 163.75 crore during the previous year ended March 2024. Sales rose 44.74% to Rs 1029.99 crore in the year ended March 2025 as against Rs 711.60 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 340.45183.95 85 1029.99711.60 45 OPM % 41.1128.85 - 36.6732.21 - PBDT 152.1761.87 146 423.89257.92 64 PBT 147.2254.15 172 406.10229.83 77 NP 110.1039.65 178 305.20163.75 86
&w=3840&q=100)
Business Standard
30-04-2025
- Business
- Business Standard
Blue Jet Healthcare jumps 6% as MOFSL initiates coverage, 26% upside seen
Blue Jet Healthcare share price today: Shares of pharma company Blue Jet Healthcare surged around 6.5 per cent on Wednesday to hit an intraday high of ₹730.10 on the NSE after Motilal Oswal Financial Services (MOFSL) initiated its coverage with a 'Buy' rating. The brokerage firm has set a target price of ₹865, which shows an upside of 26 per cent from its last closing price of ₹685.40. According to analysts at MOFSL, the company has established itself as a reliable supplier of Contrast Media and Pharmaceutical Intermediaries & API to its customers for the past three decades. It is now significantly increasing its investment in research and development (R&D) to move up the value chain. At 2:38 PM on Wednesday, Blue Jet Healthcare's stock was quoting at ₹715, up 4.32 per cent on the National Stock Exchange (NSE). In comparison, the benchmark Nifty50 index was trading at 24,330.95, down 5 points or 0.02 per cent. On a year-to-date basis, the stock has surged around 21 per cent compared to a 2.9 per cent increase in the Nifty50 index. The pharma company's total market capitalisation stood at ₹12,381.96 crore. Despite subdued performance from FY20 to FY24 due to a lack of new launches, the company is poised for a sharp turnaround on the back of product ramp-ups and new launches. The company's revenue, Ebitda (earnings before interest, tax, depreciation and amortisation), and profit are likely to grow at a CAGR (compound annual growth rate) of 27 per cent, 24 per cent and 19 per cent, respectively, over FY25-27E. It expects an average Ebitda margin of 35.1 per cent during the same period. During FY25-27E, the brokerage expects Blue Jet to record free cash flow (FCF) of ₹360 crore and cumulative capex (capital expenditure) of ₹500 billion. "Blue Jet Healthcare's revenue growth will be driven by new products in iodinated and gadolinium contrast media, NCE intermediates, and a high-intensity sweetener variant. The PI/API segment is also set for strong growth, with ramp-up in supplies for Esperion's Bempedoic acid in coming quarters," the brokerage said. Recently, the company commissioned Plant 6 at unit 2 in Ambernath with an investment of ₹90 crore, adding 120 KL capacity for PI and contrast media. In addition, it started cardiovascular PI production in mid-September 2024, increased R&D into advanced platforms and bolstered talent for CDMO growth. ALSO READ | However, MOFSL also flagged some downside risks for the company including high product and customer concentration, delays in new product ramp-up, and lower margins. "Upside risks include a faster ramp-up of high-margin products and increased long-term contracts that could boost growth and valuations," the brokerage said. About Blue Jet Healthcare Incorporated in 1968, Blue Jet Healthcare is a pharmaceutical and healthcare ingredient company that operates as a Contract Development and Manufacturing Organisation (CDMO). It primarily focuses on contrast media intermediates, high-intensity sweeteners, pharmaceutical intermediates and APIs. It has a presence in over 50 countries across the United States, Europe and Asia.
Business Standard
30-04-2025
- Business
- Business Standard
Blue Jet Healthcare jumps after broker initiates 'buy' rating
Shares of Blue Jet Healthcare rose 4% to Rs 713 after a domestic brokerage initiated coverage on the stock with a 'Buy' rating and a target price of Rs 865. The broker cited a favourable outlook supported by the company's ability to scale up high-margin products and secure more long-term contracts, which could potentially enhance both growth and valuations. The brokerage noted that Blue Jets advanced research and development capabilities, along with its backward integration and expertise in complex chemistries, position it well to serve both regulated and emerging markets. These factors, it said, place the company at the forefront of delivering high-value pharma solutions. Looking ahead, the brokerage expects Blue Jet's revenue growth to be fueled by its pipeline of new products in iodinated and gadolinium contrast media, novel chemical entity (NCE) intermediates, and innovations in high-intensity sweeteners. Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization ("CDMO") business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. On a standalone basis, net profit of Blue Jet Healthcare soared 208.25% to Rs 98.98 crore while net sales climbed 90.92% to Rs 318.38 crore in Q3 December 2024 over Q3 December 2023.
